Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies
- PMID: 1724954
- DOI: 10.1159/000463204
Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies
Abstract
Three monoclonal antibodies (mabs), two against C5 and one against C6, were identified and characterized. They inhibited the generation of the terminal complement complex (TCC) in serum to over 90% as assayed by a sensitive ELISA based on a neoepitope-specific mab, which recognized TCC-integrated C9. The haemolytic function of the TCC was markedly reduced by all three mabs implying that they are directed to epitopes on C5 and C6 which are essential for TCC formation in both the fluid phase and on erythrocyte membranes. Since the generation of C5a was also impaired by these mabs, they may serve as tools in investigations of the sequelae of the generation of C5a and of TCC.
Similar articles
-
Determination of the number of lytic sites in biconcave and spheroid erythrocyte ghosts after complement lysis.J Immunol. 1979 May;122(5):2032-6. J Immunol. 1979. PMID: 448115 No abstract available.
-
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex.Scand J Immunol. 1985 Aug;22(2):197-202. doi: 10.1111/j.1365-3083.1985.tb01871.x. Scand J Immunol. 1985. PMID: 2412280
-
An enzyme-linked immunoabsorbent assay for the quantitation of the terminal complement complex from cell membranes or in activated human sera.J Immunol Methods. 1986 Dec 24;95(2):217-25. doi: 10.1016/0022-1759(86)90409-6. J Immunol Methods. 1986. PMID: 3794343
-
Interactions of complement with the red-cell membrane.Semin Hematol. 1979 Apr;16(2):128-39. Semin Hematol. 1979. PMID: 384519 Review.
-
Activation-dependent epitopes in the terminal complement pathway.Complement Inflamm. 1989;6(3):223-35. doi: 10.1159/000463096. Complement Inflamm. 1989. PMID: 2472924 Review.
Cited by
-
A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure.Clin J Am Soc Nephrol. 2009 Aug;4(8):1356-62. doi: 10.2215/CJN.06281208. Epub 2009 Jul 9. Clin J Am Soc Nephrol. 2009. PMID: 19590060 Free PMC article.
-
Clinical utility of complement assessment.Clin Diagn Lab Immunol. 1995 Sep;2(5):509-17. doi: 10.1128/cdli.2.5.509-517.1995. Clin Diagn Lab Immunol. 1995. PMID: 8548527 Free PMC article. Review. No abstract available.
-
An abnormal but functionally active complement component C9 protein found in an Irish family with subtotal C9 deficiency.Immunology. 2003 Mar;108(3):384-90. doi: 10.1046/j.1365-2567.2003.01587.x. Immunology. 2003. PMID: 12603605 Free PMC article.
-
Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.J Virol. 2008 Apr;82(8):3834-42. doi: 10.1128/JVI.02569-07. Epub 2008 Jan 30. J Virol. 2008. PMID: 18234794 Free PMC article. Clinical Trial.
-
Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.J Clin Invest. 1995 Sep;96(3):1564-72. doi: 10.1172/JCI118195. J Clin Invest. 1995. PMID: 7657827 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous